share_log

Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis

Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis

Aurinia製藥公司獲得歐盟委員會批准Lupkynis用於治療成人活動性狼瘡性腎炎
Benzinga Real-time News ·  2022/09/15 12:04

Aurinia Pharmaceuticals Gets European Commission Approval Of Lupkynis For The The Treatment Of Adults With Active Lupus Nephritis

Aurinia製藥公司獲得歐盟委員會批准Lupkynis用於治療成人活動性狼瘡性腎炎

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論